文献速递乳腺癌

HER2阳性乳腺癌新辅助化疗后间质淋巴细胞浸润与侵袭性残留病变及无病生存期降低相关

Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究纳入2002至2011年间175例接受新辅助化疗±曲妥珠单抗的原发性HER2阳性乳腺癌患者,评估化疗前后间质淋巴细胞浸润水平及其与病理完全缓解和无病生存的关系。基线TIL水平与pCR无显著相关,78%患者治疗期间TIL下降,下降幅度与pCR强相关;残留病灶中TIL>25%与不良结局显著相关(HR=7.98,P=0.009)。

要点

  • 基线TIL水平与pCR无显著相关。
  • 78%患者治疗期间TIL下降,下降幅度与pCR强相关。
  • 残留病灶中TIL>25%与不良结局显著相关(HR=7.98,P=0.009)。

核心结论

  • 化疗期间TIL下降与治疗反应正相关;未达pCR者新辅助化疗后淋巴细胞浸润与更高残留肿瘤负荷及不良临床结局相关。

研究设计与样本

  • 研究纳入2002至2011年间175例接受新辅助化疗±曲妥珠单抗的原发性HER2阳性乳腺癌患者,配对评估微生物活检标本与手术标本的间质淋巴细胞浸润,采用单因素和多因素分析评估临床病理因素与pCR及无病生存的关联。

主要发现

  • 基线TIL水平与pCR无显著相关。
  • 78%的患者治疗期间TIL水平下降,下降幅度与pCR强相关。
  • 化疗后TIL水平在侵袭性模式肿瘤中较高(高残留癌症负荷评分、核分裂指数>22、肿瘤细胞密度>5%)。
  • 在残留病灶人群中,新辅助化疗结束时TIL>25%与不良结局显著相关(TIL>25%,HR=7.98,P=0.009),多因素分析纳入BMI、新辅助化疗后核分裂指数和肿瘤分级。

关键数值与推荐

  • 残留病灶人群中新辅助化疗后TIL>25%与不良结局显著相关(HR=7.98,P=0.009)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以表征残留病灶中的免疫浸润,识别可从包括免疫检查点抑制剂在内的二线治疗试验中获益的候选者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade. High TILs levels have been associated with pathological response rate in the neoadjuvant setting and with better outcomes in the adjuvant setting. However, little attention has been paid to changes in TILs and residual TIL levels after neoadjuvant chemotherapy (NAC). We investigated TIL levels before, after chemotherapy, and their dynamics during treatment; and we assessed the correlation of these levels with response to NAC and prognosis. MATERIALS AND METHODS: We identified 175 patients with primary HER2-positive breast cancers receiving NAC+/- trastuzumab between 2002 and 2011. Microbiopsy specimens and paired surgical samples were evaluated for stromal lymphocyte infiltration. Univariate and multivariate analyses were carried out to assess the association of clinical and pathological factors with pathological complete response (pCR) and disease-free survival. RESULTS: Baseline TIL levels were not significantly associated with pCR. TIL levels decreased during treatment in 78% of the patients. The magnitude of the decrease was strongly associated with pCR. After chemotherapy, TIL levels were high in tumors displaying aggressive patterns (high residual cancer burden score, mitotic index >22, tumor cellularity >5%). In the population with residual disease, TIL levels >25% at the end of NAC were significantly associated with an adverse outcome (TILs >25%, HR = 7.98, P = 0.009) after multivariate analyses including BMI, post-NAC mitotic index and tumor grade. CONCLUSION: A decrease in TIL levels during chemotherapy was positively associated with response to treatment. In tumor failing to achieve pCR, post-NAC lymphocytic infiltration was associated with higher residual tumor burden and adverse clinical outcome. Further studies are required to characterize immune infiltration in residual disease to identify candidates who could benefit from second-line therapy trials including immune checkpoint inhibitors.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hamy AS, Pierga JY, Sabaila A, et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. 2017. PMID: 28911063. doi:10.1093/annonc/mdx309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。